Tuesday, February 26, 2019

Is Kohl's Creating the Department Store of the Future?

More than any other retailer, Kohl's (NYSE:KSS) is arguably doing the most to change how we think about department stores in a bid to stave off the threat of irrelevance that's overtaken much of bricks-and-mortar retailing.

In just the last two years alone, Kohl's has launched the following initiatives to transform its stores into a different kind of retailing experience:

Partnered with Amazon.com to create store-in-store boutiques to sell Alexa-enabled devices. Agreed to serve as an Amazon package return center for items bought on the e-commerce website. Convinced Under Armor to sell its sportswear in its stores, an outlet that had never been tried before. Made a decisive move to separate itself further from shopping malls, closing four more mall-based stores this year, but opening four smaller stand-alone locations (most Kohl's stores are not in malls). Shrank the available floor space of some of its larger stores and used the unused square footage in 10 of them to allow discount supermarket chain Aldi to rent out the space.

The latest example of this re-imagination of the department store is its partnering with WW, the new name of Weight Watchers International, to install weight-loss studios in its stores.

Amazon.com boutique inside Kohl's

Image source: Kohl's.

An idea as old as time

The department store really hasn't changed much since 150 years ago, when Harry Selfridge largely created the shopping experience we know today: stores featuring a number defined spaces devoted to a particular category; employees helping customers make a purchase; so-called "bargain basements"; and marketing stores through advertising. We can also thank Selfridge for the phrases "the customer is always right" and "only xx days until Christmas!"

While the stores themselves have barely changed, the habits of consumers have greatly evolved, which explains why the department store and, by extension the shopping malls they anchor, stand on the edge of extinction. There's perhaps no greater irony for the retail industry than Amazon taking over the Rolling Acres Mall in Akron, Ohio, that closed in 2013 to redevelop it into a 695,000-square-foot distribution facility for its e-commerce site.

Retailers have been slow to change, to understand the new dynamic of how consumers want to shop, and that is leading to their demise. 

Are you experienced?

Although today we hear more about "experiential" shopping -- a largely meaningless catchphrase a number of retailers have latched onto to separate them from the competition even though there is no one definition for what it means -- we see companies expressing it in odd ways.

Last month, Foot Locker opened its first "power store" in the Detroit area that is intended to serve as a "hub for local sneaker culture, art, music and sport." It also has "activation space" for people or product launches, like the Adidas AM4DET sneaker, a graffiti-covered shoe supposedly inspired by the city.

Samsung will open its three "experiential retail locations," its first true physical stores ever -- that look like a typical Apple store -- where you can test out all of the electronics maker's gear.

Nordstrom opened three Local stores that sell everything but what a customer presumably goes to Nordstrom for (clothes), while high-end furniture chain West Elm opened a half-dozen hotels to subtly sell its products.

Staying within its core competency

Rather than going so far afield, Kohl's seems to be providing consumers with actual new ways to think about what it means to go to one of its stores by playing to its strength and leveraging its physical store space. It's not running away from the fact that it's a retailer, but rather giving customers more reasons and benefits to see Kohl's as a destination.

Former J.C. Penney CEO Ron Johnson sought to remake the troubled retailer into something similar, though he was fired before he could turn his ideas into reality.

Not every Kohl's location will have each of these opportunities, nor will all of them will work. But as the retailer continues to explore the boundaries of what makes a customer want to come to shop and stay, we'll likely see these ideas and more expand into more locations.

While other retailers also experimented with having outside retailers take up residence in their stores, Kohl's could be the one that redefines what it means to be a department store by innovating in ways that are meaningful to its customers and its bottom line.

Sunday, February 24, 2019

Fidelity notches record profit and revenue despite a slowdown in stock markets

Fidelity Investments had a historic 2018, even as stock markets saw their worst performance in a decade.

For the first time in history, Fidelity's annual income topped $6 billion. It closed 2018 with a 19 percent increase in operating income, totaling $6.3 billion for the year. The Boston-based firm raked in a record $20.4 billion in revenue last year, a roughly 12 percent increase from a year earlier, according to Fidelity's annual report.

The results were helped by diversity in Fidelity's businesses as the firm made "extensive moves" to add product and service offerings across the retail brokerage, workplace benefits, and institutional investing, Fidelity chairman and chief executive Abigail Johnson said in a letter to shareholders.

The strong results highlight success of Fidelity's years-long effort to add new lines of business aside from just stock-picking.

"Fidelity's diverse group of businesses and broad set of investment solutions helped to offset the negative effects that the stock market's decline would have otherwise had on the company's asset levels," Johnson said in the annual shareholder letter.

Markets stumbled late last year with major indexes posting their worst performance in a decade. The S&P 500 lost 6 percent in 2018. For Fidelity, assets under administration declined 1.5 percent at the end of last year, totaling $6.69 trillion. Assets under administration includes the money Fidelity oversees for retirement account and brokerage clients.

For the asset management business, the fourth-quarter turmoil was a "significant detractor to Fidelity's equity performance for the year," Stephen Neff, president of Fidelity Asset Management said in the letter. Still, asset management delivered solid performance. In aggregate, Fidelity said its mutual funds outperformed peers by 66 percent, 72 percent, and 76 percent for the trailing one, three, and five-year periods respectively.

Last summer, the company announced a suite of zero-fee funds for retail investors. They offer zero investment and account minimums, no fees and no domestic money movement fees. From the start of August to the end of last year, clients ushered $2.9 billion of assets into those new "ZERO" funds, Johnson said.

The firm's total customer base also grew last year. Fidelity, which was founded by the Johnson family in 1946, serviced 31.1 million workplace and health care participants in 2018, a 6 percent increase from a year earlier. Its 20.8 million retail clients were up 7 percent from a year earlier, and the 7.1 million accounts managed by intermediaries on Fidelity's clearing and custody platform grew 6.5 percent from year-end 2017.

The family-controlled firm is known for managing retirement plans and mutual funds. But it also spends roughly $2.5 billion per year in technologies like blockchain and artificial intelligence through Fidelity Labs and its Fidelity Center for Applied Technology. In October, it branched out with a new company, Fidelity Digital Asset Services, to offer custody service for cryptocurrencies. The new company implemented its first institutional client in December, according to the shareholder letter.

Friday, February 22, 2019

Top 5 Biotech Stocks For 2019

tags:AMGN,ARQL,BIIB,ALNY,

Shares of struggling biotech EyeGate Pharmaceuticals (EYEG) have fallen by nearly 70% over the past year. However, the stock has risen 17% year to date as the current move appears to have legs.

The stock popped back onto my radar in late April when one member in Live Chat pointed out significant insider buying had taken place.

Chart

Figure 1: EYEG daily advanced chart (source: Finviz)


Figure 2: EYEG 15-minute chart (source: Finviz)

Top 5 Biotech Stocks For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:
  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 11.32 million shares from the previous level of 10.78 million. Shares were last seen trading at $142.15, in a 52-week trading range of $141.09 to $217.00.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.72 million shares from the previous level of 9.62 million. Shares were last seen at $184.61 in a 52-week trading range of $161.13 to $201.23.

  • [By Logan Wallace]

    AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

Top 5 Biotech Stocks For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:
  • [By Cory Renauer]

    What's behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

Top 5 Biotech Stocks For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:
  • [By Lisa Levin]

    Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.

    Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.

  • [By Todd Campbell]

    The acquisition of AveXis resulted in an $80 million milestone payment to Regenxbio in Q1 and an additional $100 million payment in June. If AVXS-101 wins an OK, Regenxbio will receive sales royalties in the mid single to low double digits, which could add up to hundreds of millions of dollars annually. For perspective, Biogen's (NASDAQ:BIIB) Spinraza became the only FDA-approved treatment for SMA in late 2016, and its sales are already tracking at an annualized pace of over $1.2 billion, even though only 40% of patients see an improvement on it.

  • [By George Budwell]

    Shares of large-cap biotech Biogen (NASDAQ:BIIB) gained a healthy 15.2% in July, according to data from S&P Global Market Intelligence. What triggered this breakout? 

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already. 

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.

  • [By Steve Symington]

    But several individual stocks lagged the broader market. Read on to see why Cerner (NASDAQ:CERN), Biogen (NASDAQ:BIIB), and Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) slumped today.

Top 5 Biotech Stocks For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:
  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Orelli]

    Earlier this week, Dicerna released promising interim phase I data for its lead drug, DCR-PHXC, in patients with primary hyperoxaluria type 1 and type 2. The company plans to start a trial to be used to support an FDA approval in the first quarter of 2019, but that'll put it behind Alnylam Pharmaceuticals (NASDAQ:ALNY), which is about to start a phase 3 study testing its drug, lumasiran, in patients with primary hyperoxaluria type 1. Hopefully, Dicerna can use some of its new capital to help accelerate enrollment in its trial to try to catch up to Alnylam.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Todd Campbell]

    Spark Therapeutics (NASDAQ:ONCE) reported its hemophilia A drug significantly reduced bleeding events and the need for prophylactic factor VIII infusions, but investors sold shares on worry that the gene therapy's safety could be a problem. Investors similarly headed for the exits with Rite Aid (NYSE:RAD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) after the former scuttled an attempt to sell itself and the latter secured a first-in-class FDA approval. Are these falling stocks worth buying?

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

Wednesday, February 20, 2019

AutoZone (AZO) Reaches New 52-Week High at $922.28

AutoZone, Inc. (NYSE:AZO) reached a new 52-week high on Monday . The company traded as high as $922.28 and last traded at $919.75, with a volume of 293014 shares changing hands. The stock had previously closed at $904.96.

Several research analysts have issued reports on AZO shares. Zacks Investment Research upgraded shares of AutoZone from a “hold” rating to a “buy” rating and set a $976.00 price target for the company in a report on Monday, December 17th. Morgan Stanley raised their price target on shares of AutoZone from $870.00 to $900.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 23rd. Wedbush set a $870.00 price target on shares of AutoZone and gave the stock a “buy” rating in a report on Wednesday, November 21st. Credit Suisse Group lifted their price objective on shares of AutoZone from $854.00 to $930.00 and gave the company an “outperform” rating in a research note on Thursday, December 6th. Finally, Wells Fargo & Co reiterated a “buy” rating and issued a $970.00 price objective on shares of AutoZone in a research note on Tuesday, December 4th. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $882.51.

Get AutoZone alerts:

The company has a market cap of $23.18 billion, a PE ratio of 18.27, a P/E/G ratio of 1.24 and a beta of 0.68.

AutoZone (NYSE:AZO) last issued its quarterly earnings results on Tuesday, December 4th. The company reported $13.47 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $12.21 by $1.26. The company had revenue of $2.64 billion during the quarter, compared to the consensus estimate of $2.64 billion. AutoZone had a negative return on equity of 102.31% and a net margin of 12.49%. AutoZone’s revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the firm posted $10.00 EPS. On average, equities analysts forecast that AutoZone, Inc. will post 59.67 EPS for the current year.

In other AutoZone news, insider Ronald B. Griffin sold 21,000 shares of the company’s stock in a transaction on Monday, December 17th. The shares were sold at an average price of $844.93, for a total transaction of $17,743,530.00. Following the sale, the insider now directly owns 21,377 shares of the company’s stock, valued at $18,062,068.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP William T. Giles sold 13,500 shares of the company’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $870.11, for a total transaction of $11,746,485.00. Following the sale, the vice president now directly owns 13,119 shares in the company, valued at $11,414,973.09. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,790 shares of company stock valued at $40,211,001. 2.80% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Polianta Ltd purchased a new position in AutoZone during the 4th quarter worth $1,173,000. State Treasurer State of Michigan boosted its stake in AutoZone by 413.3% in the 4th quarter. State Treasurer State of Michigan now owns 40,364 shares of the company’s stock worth $33,839,000 after purchasing an additional 32,500 shares during the period. IFM Investors Pty Ltd boosted its stake in AutoZone by 13.3% in the 3rd quarter. IFM Investors Pty Ltd now owns 1,446 shares of the company’s stock worth $1,122,000 after purchasing an additional 170 shares during the period. Nippon Life Global Investors Americas Inc. acquired a new position in AutoZone in the 4th quarter worth approximately $2,691,000. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in AutoZone by 353.8% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 6,362 shares of the company’s stock worth $4,935,000 after purchasing an additional 4,960 shares during the period. 88.94% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “AutoZone (AZO) Reaches New 52-Week High at $922.28” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4162010/autozone-azo-reaches-new-52-week-high-at-922-28.html.

About AutoZone (NYSE:AZO)

AutoZone, Inc retails and distributes automotive replacement parts and accessories. The company offers various products for cars, sport utility vehicles, vans, and light trucks, including new and remanufactured automotive hard parts, maintenance items, accessories, and non-automotive products. Its products include A/C compressors, batteries and accessories, bearings, belts and hoses, calipers, carburetors, chassis, clutches, CV axles, engines, fuel pumps, fuses, ignition and lighting products, mufflers, radiators, starters and alternators, thermostats, and water pumps.

See Also: Correction

Tuesday, February 19, 2019

GSK Consumer Healthcare falls 2% after Credit Suisse downgrades, cuts price target

GlaxoSmithKline Consumer Healthcare shares fell 2 percent in morning on Monday after global research firm Credit Suisse downgraded the stock to neutral from outperform despite strong earnings growth in December quarter.

The brokerage also slashed its price target by 7.4 percent to Rs 8,330 from Rs 9,000 apiece earlier as healthy volume growth and margin tailwinds may be behind.

GSK Consumer's profit in quarter ended December 2018 grew by 35 percent to Rs 221 crore and revenue increased by 7.42 percent to Rs 1,116 crore compared to a year-ago.

At operating level, EBITDA (earnings before interest, tax, depreciation and amortisation) jumped 15 percent to Rs 238.53 crore and margin expanded by 140 bps to 21.38 percent YoY.

related news D-Street Buzz: IT stocks in red dragged by KPIT Tech; Dr Reddy's Labs jumps 2%, Yes Bank falls Glenmark Pharma rises 4% on USFDA final approval

Meanwhile, in December 2018, the company had announced divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc and the merger of GSK Consumer Healthcare with Hindustan Unilever Limited (HUL).

On January 23 this year, the merger deal with Hindustan Unilever Limited (HUL) was approved by the Competition Commission of India (CCI).

"The merger is now subject to the receipt of other necessary statutory and regulatory approvals under applicable laws. The merger process is moving along expected timelines," the company added.

GSK's merger with HUL is expected to be completed before December 2019 and the stock is now a proxy for HUL, Credit Suisse said.

At 10:01 hours IST, the stock was quoting at Rs 7,276.80, down Rs 151.35, or 2.04 percent on the BSE.

Disclaimer: The above report is compiled from information available on public platforms. Moneycontrol advises users to check with certified experts before taking any investment decisions. First Published on Feb 18, 2019 10:20 am

Sunday, February 17, 2019

Why Mattel Stock Plunged Today

What happened

A week after Mattel (NASDAQ:MAT) stock surged on a better-than-expected fourth-quarter earnings report, the stock was giving up much of those gains after Mattell issued 2019 guidance today at the New York Toy Fair. The toy maker said it expected flat gross sales in constant currency for the year, and said weakness in its Thomas & Friends and American Girl brands would weigh on performance.

As a result, the stock finished the day down 18.3%.

A Barbie figurine with accessories

Image source: Mattel.

So what

In a presentation at the industry's biggest annual gathering, Mattel CFO Joe Euteneuer said that first-quarter sales would decline as the company laps the Toys R Us bankruptcy, sees a slight sales decline in China, and faces the effects of a strong dollar. Euteneuer also noted that Easter was shifting into the second quarter, bringing toy sales with it. The company said the Barbie and Hot Wheels brands would continue to grow, but momentum would ease from last year. 

In the second quarter, the company saw sales momentum picking up with the release of Toy Story 4 and Jurassic World, and said there were no meaningful year-over-year comparisons for the second half of the year.

On the cost side, it said it would save at least $278 million more on expenses including input costs, marketing, and selling, general, and administrative costs as it continues to implement a multiyear cost-cutting program.  

Finally, the company sees gross margin improving from 39.8% to the low 40s, and projects a slightly positive adjusted operating profit, up from a loss of $115 million last year.  

Now what

Mattel's forecast compares unfavorably with the analyst consensus of 3.9% revenue growth to $4.61 billion. On the bottom line, analysts saw the company posting an adjusted profit per share of $0.05 after a loss of -$0.84 in 2018. Though Mattel didn't provide earnings per share (EPS) guidance, its expected $190 million in interest expense is sure to negate its slight adjusting operating profit, leading to a bottom-line loss.

Though the company continues to tout the potential of its intellectual property in things like movies, games, and TV shows, the numbers speak for themselves. It's not a surprise to see the stock diving with the company's forecast.

Why Did CenturyLink Decide to Cut Its Dividend?

CenturyLink (NYSE:CTL) shareholders got some unwelcome news last week...

... or did they?

On the company's fourth-quarter earnings conference call, management disclosed it would be cutting the telecom service provider's annual dividend from $2.16 to $1.00 per share. CenturyLink's share price had declined a lot since summer, driving its dividend yield over 15%, so clearly some investors anticipated this possibility. Even after the cut, CenturyLink's yield stands at over 7%.

Still, many were surprised, since management had regularly expressed confidence in the dividend throughout 2018, and the company's free cash flow handily covered the payout. So why did management make this decision?

A young man grimaces as dollar bills fly out of his wallet.

CenturyLink's dividend cut irked some investors. Image source: Getty Images.

What management had to say

On the company's earnings call, CEO Jeff Storey said:

... this change in policy isn't about a diminished view of our business. It is driven by our view that the long-term interests of shareholders are best served by proactively accelerating delevering to a new lower target range of 2.75 to 3.25 times net-debt to adjusted EBITDA ... By reallocating more of our capital to leverage reduction, we believe [we] will improve our cost of capital, return a significant amount of cash to shareholders at a very sustainable payout ratio, and provide additional flexibility to respond to market opportunities and any potential interest rate challenges that may occur.

In essence, management thinks even though CenturyLink could preserve the dividend, it would be better for the long-term health of the business to invest in the network, lower the company's $36 billion debt load, or make potential acquisitions. CenturyLink is also still saddled with some legacy copper-based products, such as landline phones and slower internet. Those headwinds are currently more than offsetting the company's fiber-based growth businesses, leading to current revenue declines on an overall basis.

The new debt-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) range is a three-year target, reflecting not only the debt paydown, but also EBITDA growth from investments in new products and capabilities.

An analyst pushes back

Many investors, and at least one analyst, may have been confused by management's decision, especially in light of pretty decent 2019 guidance. For the upcoming year, CenturyLink guided to a slight increase in adjusted EBITDA, from $8.94 billion last year to a range of $9.0 billion-$9.2 billion in 2019. However, the company's free cash flow guidance was $3.1 billion-$3.4 billion, down from this year's adjusted free cash flow of $4.22 billion, due to increased capital expenditures and the comparative effect of a lowered tax expense in 2018. Still, that free cash flow guidance would have handily covered the old $2.3 billion dividend payout -- though as we'll see below, just covering the dividend payout doesn't tell the whole story. 

Analyst David Barden of Bank of America pushed back on management's decision to pay down debt early, asking, "...between the $6 billion of cash flow that you're gonna generate and the $3.6 billion of debt that matures and everything's trading above par, [it] doesn't really make sense to pay it down early."

Barden's point was that while CenturyLink has over $36 billion in debt, only $3.6 billion matures over the next three years. Those bonds are all trading "above par," meaning that bond investors did not appear worried about CenturyLink's ability to service that debt.

I'm not sure Barden's numbers were correct, unless something has changed since CenturyLink's last quarterly report. As of its third-quarter report, it looks like roughly $5 billion is set to mature in that time frame, with another $5.3 billion due the following year in 2022.

Year

CenturyLink Long-Term Debt Maturities (in millions)

2019

$651

2020

$1,202

2021

$3,115

2022

$5,323

2023 and thereafter

$25,785

Data source: CenturyLink Q3 10Q. Table by author.

Of course, CenturyLink doesn't necessarily have to pay all debt when due, if it can refinance it with new notes. However, given the rising interest rate environment and the market dislocation in December, it appears management didn't want to take that risk. If a company needs to refinance a lot of debt, there's no guarantee it will obtain the interest rate it likes, and if there's a market crash, debt markets may not be open at all.

CFO Neel Dev said, "Our view is paying down about a couple billion of long-term obligations per year over the next three years makes sense, but you have a different view." 

Safety first

While it appears CenturyLink had the ability to pay the old dividend, reduce debt, and invest in its network, management apparently decided things were too close for comfort and is taking pre-emptive action. While dividend-focused investors are likely disappointed, the de-risking of the business was likely the safest move. Removing the debt maturity risk overhang could even help CenturyLink's flailing share price in the medium term, which investors shouldn't mind at all.

Saturday, February 16, 2019

Vericel Corp (VCEL) Stake Increased by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC grew its position in Vericel Corp (NASDAQ:VCEL) by 2.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 157,372 shares of the biotechnology company’s stock after buying an additional 3,048 shares during the period. Essex Investment Management Co. LLC owned 0.36% of Vericel worth $2,738,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in shares of Vericel by 17.1% in the 3rd quarter. Legal & General Group Plc now owns 6,443 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 943 shares during the last quarter. Meeder Asset Management Inc. raised its position in Vericel by 28.7% during the 4th quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock worth $100,000 after buying an additional 1,284 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Vericel during the 4th quarter worth approximately $44,000. Financial Architects Inc purchased a new position in Vericel during the 4th quarter worth approximately $69,000. Finally, American International Group Inc. raised its position in Vericel by 18.6% during the 3rd quarter. American International Group Inc. now owns 28,505 shares of the biotechnology company’s stock worth $403,000 after buying an additional 4,474 shares during the last quarter. Institutional investors and hedge funds own 79.31% of the company’s stock.

Get Vericel alerts:

In related news, CFO Gerard J. Michel sold 10,000 shares of Vericel stock in a transaction on Monday, February 11th. The shares were sold at an average price of $17.09, for a total value of $170,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steven C. Gilman sold 8,500 shares of Vericel stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $17.75, for a total transaction of $150,875.00. Following the completion of the sale, the director now directly owns 8,500 shares in the company, valued at approximately $150,875. The disclosure for this sale can be found here. Insiders sold a total of 65,336 shares of company stock worth $1,112,761 in the last three months. 4.70% of the stock is owned by corporate insiders.

Several research firms have recently weighed in on VCEL. BidaskClub raised shares of Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. Needham & Company LLC lifted their target price on shares of Vericel to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 6th. BTIG Research lifted their target price on shares of Vericel from $17.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, November 6th. Finally, Oppenheimer began coverage on shares of Vericel in a report on Tuesday, January 29th. They set an “outperform” rating and a $23.00 target price for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $18.00.

Vericel stock opened at $19.21 on Friday. Vericel Corp has a 1 year low of $6.80 and a 1 year high of $19.24. The firm has a market capitalization of $785.45 million, a P/E ratio of -38.42 and a beta of 2.92. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.71 and a current ratio of 7.96.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/4154611/vericel-corp-vcel-stake-increased-by-essex-investment-management-co-llc.html.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Read More: Why do companies issue convertible shares?

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Friday, February 15, 2019

Yelp Earnings: YELP Stock Soars After Crushing Q4 Earnings

Yelp earnings (NYSE:YELP) came in stronger than what Wall Street was calling for by a ratio of nearly 4 to 1, while revenue also topped expectations, helping to lift YELP stock more than 5% after the bell Wednesday.

Yelp EarningsYelp Earnings Source: Shutterstock

For its fourth quarter of its fiscal 2018, the San Francisco-based company announced that it closed out the year on a high note as it brought in adjusted earnings of 37 cents per share. Wall Street said in its consensus estimate that it saw the company amassing adjusted earnings of 10 cents per share, which was compiled from a survey of analysts conducted by Refinitiv.

Yelp added that it raked in revenue of $244 million for the period, handily beating the $241 million that the Refinitiv forecast called for. The review site company’s board had previously announced that it had authorized a share repurchase program amounting to $250 million worth of YELP stock–the company doubled the buyback amount to $500 million in a Wednesday announcement.

The company also revealed that it has added three new board members to its fold in Twilio COO George Hu, Stripes Group Operating Partner Sharon Rothstein, as well as HomeAway co-founder Brian Sharples. Yelp said they will begin their terms on March 1, replacing Geoff Donaker, Jeremy Levine and Peter Fenton.

YELP stock is up about 6% following the review site operator’s monster quarterly performance to close out its fiscal 2018. Shares had been dipping more than 1.2% during regular trading hours as the company readied itself to report its results.

Compare Brokers

Wednesday, February 13, 2019

Bosses, Beware! You're Legally at Risk Over High 401(k) Plan Fees

A good 401(k) plan can be an amazing tool for helping to build your retirement nest egg. Most companies offer at least some level of employer match, and the tax deferral is a great perk. But if your 401(k) options come larded with excessive fees, it's a whole different story.

In this segment from the Motley Fool Answers January mailbag show, hosts Alison Southwick and Robert Brokamp -- and special guest Sean Gates, a financial planner with Motley Fool Wealth Management, a sister company of The Motley Fool -- take a question from a listener whose friend is being hit with an up-front 5.75% sales fee, over and above the annual fees and expenses for the funds in his employers' plan. Their advice: You may need a lawyer, but it might be better to open the conversation a bit less adversarially.

A full transcript follows the video.

This video was recorded on Jan. 29, 2019.

Alison Southwick: The next question comes from Jim. "I was discussing 401(k) plans with a friend recently, and he showed me his statement." Wow, these are close friends! There are not many people in the world I would show my statement to. "He is paying a 5.75% sales fee upfront before the ongoing cost of the various funds. On the surface, it would seem that the plan doesn't meet the fiduciary responsibility.

"He said he asked his CEO about the plan and they won't change anything. The company doesn't provide any match, so I told him to stop contributing and use an IRA or brokerage account. Can you explain the responsibility of a plan administrator? Is there anything else that he can do?"

Sean Gates: It's a great question and very inside baseball. The responsibility rolls up to ERISA, which is the regulatory body that governs employer-provided plans. One thing that your friend can do, as a first step, is just make the CEO aware that he has a personal responsibility to provide fiduciary-level advice to his employees.

You can do that in subtle ways. You can give him reports. This is what's referred to as an "interested party." The people who actually administer the plan -- TPA people, record keepers, the actual plan administrator -- have a direct fiduciary responsibility to their employees.

But they're also interested parties, and under the new fiduciary rule that's being bandied about -- and then specifically under ERISA -- these interested parties also share responsibility. Just making him aware that he could be personally liable for any lawsuits that came against him for high-fee 401(k)s might nudge him in a different direction.

A harder step that you could take is you could initiate a class action lawsuit. There have been several over the last few years that have paid out massively, and they're not hard to prove. A 5.75% front load on a mutual fund will fall squarely in what they call "excessive fee classification." Ameriprise recently paid out $27.5 million. Boeing and Lockheed Martin had multimillion-dollar lawsuits. These lawsuits will normally be remunerative to the clients above and beyond. So it's base level, punitive damages, and then making clients whole for the fees that they paid over and above.

Southwick: It sounds like he works with a small employer if he's able to walk into a CEO's office and chat. For a class action lawsuit -- it's not a Boeing-size company.

Gates: Right. It might not be class action lawsuit. I just used those examples to say you could take legal action. If you get an independent lawyer on your own, they can also file an excessive fees lawsuit. Now, you could be worried about the ramifications of doing that in a small-employer environment. I don't fault you for that. That's why I suggested the first step be just let him know what he is responsible for.

Southwick: You've got a nice business, here. It'd be a shame if someone filed a lawsuit for your excessive mutual fund fees.

Gates: Exactly. But I think you're also in the right. If lawsuits are on the table, there's a pro/ con decision there, but these things are becoming more and more relevant. More and more lawsuits are coming up and being paid out. It's hard to justify these types of fees inside a 401(k).

Robert Brokamp: The reason the CEO is probably doing it is to save the company money, because it does cost a company to offer a 401(k) and then if they go to a broker or a financial advisor and say, "We want a 401(k) for our company, " she or he will say, "Well, we'll charge you this and make it easy on the employees or we won't charge you much and make the employees pay." That's what's going on here, probably.

The thing is over the last few years there have been many more providers aimed at small businesses with much more reasonable fees, so I would also look out there and maybe have an alternative to offer. Say, "Look, here's someone who's doing this pretty reasonably for small businesses."

Gates: That's a great point. I was going to say Betterment has a Betterment for Business program that's a very low cost and they specifically are trying to check the boxes of the different regulations. I think it's E38 of the fiduciary rules, and so you can present those as alternatives to the CEOs who might not know that there are cost-effective ways to implement 401(k) plans.

Brokamp: And I'll second Jim's advice to his friend in saying that I would first max out an IRA before I participate in a high-cost, no-match 401(k).

Southwick: We did an episode less than a year ago on what to do if your 401(k) plan stinks. That's not the exact title but look it up. It's a lot of Bro talking about other options and what you should do.

Tuesday, February 12, 2019

A bitcoin ETF is 'virtually certain,' finance expert Ric Edelman says

The road to a bitcoin ETF has seen many roadblocks, but one finance expert said it's an inevitability.

"It's virtually certain. The only question is when," Ric Edelman, founder of Edelman Financial Engines, said Monday on CNBC's "ETF Edge" at the Inside ETFs Conference in Hollywood, Florida. "The SEC has several legitimate thoughtful concerns that the industry has to overcome but I'm confident they will. Eventually we will see a bitcoin ETF and it's at that stage that I will be much more comfortable recommending that ordinary investors participate."

The Securities and Exchange Commission has long had concerns over the cryptocurrency market and how to regulate it. For one, bitcoin trading lacks a secure chain of custody like other financial markets. Secondly, the SEC has little control over price manipulation given it has no governance over overseas trading platforms.

Major financial institutions' interest and investment in finding a solution should mean a bitcoin ETF eventually comes to market, Edelman contended.

"We've got some serious players. Fidelity has made a major announcement in the custody issue. We've got Kingdom Trust and a number of other very serious players on the custody side. I'm confident that in very short order VanEck or Bitwise will satisfy the custody concern to the SEC," said Edelman.

Tom Lydon, editor-in-chief of ETFTrends.com, said he's already seen massive demand for a product like a bitcoin ETF.

"There is pent-up demand. We interview advisors all the time. Seventy-four percent say they've talked to clients about their interests in bitcoin so they need to step up when this happens because that money is going to go elsewhere," Lydon said Monday on "ETF Edge."

The Cboe refiled an application for a VanEck and SolidX bitcoin ETF to the SEC in late January. It had pulled the ETF submission roughly a week earlier on concerns the partial government shutdown would cause delays.

Disclaimer

Monday, February 11, 2019

Best Stocks To Buy Right Now

tags:JKHY,KND,EMKR,TAHO,CECO,

Zacks Investment Research lowered shares of Sibanye Gold (NYSE:SBGL) from a hold rating to a sell rating in a research note released on Wednesday.

According to Zacks, “Sibanye Gold Limited is a gold mining company. It operates two gold mines: the Kloof Driefontein Complex (KDC) and the Beatrix gold mines. Sibanye Gold Limited is based in Houghton, South Africa. “

Get Sibanye Gold alerts:

SBGL has been the topic of several other reports. ValuEngine upgraded Sibanye Gold from a strong sell rating to a sell rating in a research report on Friday, October 12th. Citigroup lowered Sibanye Gold from a neutral rating to a sell rating in a research report on Tuesday, November 6th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $2.75.

Best Stocks To Buy Right Now: Jack Henry & Associates Inc.(JKHY)

Advisors' Opinion:
  • [By Motley Fool Transcribers]

    Jack Henry & Associates Inc  (NASDAQ:JKHY)Q2 2019 Earnings Conference CallFeb. 06, 2019, 8:45 a.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Jack Henry & Associates (JKHY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Federated Investors Inc. PA lifted its stake in shares of Jack Henry & Associates, Inc. (NASDAQ:JKHY) by 227.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,518 shares of the technology company’s stock after purchasing an additional 69,837 shares during the quarter. Federated Investors Inc. PA’s holdings in Jack Henry & Associates were worth $13,104,000 as of its most recent SEC filing.

Best Stocks To Buy Right Now: Kindred Healthcare, Inc.(KND)

Advisors' Opinion:
  • [By Stephan Byrd]

    Here are some of the media stories that may have effected Accern’s analysis:

    Get Kindred Healthcare alerts: Global Home Healthcare Mornitoring Device Market 2018 Philips Healthcare (Netherlands), Kindred Healthcare (US) (trueindustrynews.com) Recent Movement: Kindred Healthcare (NYSE: KND) (tradingnewsnow.com) Global Home Healthcare Mornitoring Device Market 2018 – Kindred Healthcare, Linde Group, Almost Family Inc. (sectorhealthcare.com) Humana, TPG Capital, and Welsh, Carson, Anderson & Stowe Create the Country’s Largest Hospice Provider, "Kindred … (jdsupra.com) Kindred Healthcare, Inc. (KND) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)

    A number of equities research analysts recently commented on KND shares. Zacks Investment Research upgraded Kindred Healthcare from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Wednesday, April 18th. ValuEngine lowered Kindred Healthcare from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Finally, TheStreet lowered Kindred Healthcare from a “c-” rating to a “d+” rating in a research report on Tuesday, May 15th. Three equities research analysts have rated the stock with a sell rating and five have issued a hold rating to the company. The stock currently has an average rating of “Hold” and an average target price of $8.33.

Best Stocks To Buy Right Now: EMCORE Corporation(EMKR)

Advisors' Opinion:
  • [By Ethan Ryder]

    EMCORE Co. (NASDAQ:EMKR) traded up 8% during mid-day trading on Monday . The stock traded as high as $5.10 and last traded at $5.26. 11,341 shares changed hands during trading, a decline of 95% from the average session volume of 216,974 shares. The stock had previously closed at $4.87.

  • [By Max Byerly]

    News stories about EMCORE (NASDAQ:EMKR) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EMCORE earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the semiconductor company an impact score of 45.6118508960632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is the most shorted stock on the NASDAQ with short interest of 62.65% according to Highshortnterest.com.

  • [By Stephan Byrd]

    EMCORE Co. (NASDAQ:EMKR) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.00.

Best Stocks To Buy Right Now: Tahoe Resources, Inc.(TAHO)

Advisors' Opinion:
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Tahoe Resources (TAHO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Neha Chamaria]

    Shares of Tahoe Resources (NYSE:TAHO) can't seem to find a bottom. The gold and silver mining stock tumbled 23.1% in August, according to data provided by S&P Global Market Intelligence, hitting multiyear lows.

  • [By Logan Wallace]

    Tahoe Resources (TSE:THO) (NASDAQ:TAHO) – Equities research analysts at National Bank Financial reduced their FY2018 earnings estimates for shares of Tahoe Resources in a research report issued on Monday, April 9th. National Bank Financial analyst M. Parkin now forecasts that the company will earn $0.29 per share for the year, down from their prior forecast of $0.35. National Bank Financial currently has a “Sector Perform” rating and a $8.00 price objective on the stock.

  • [By Maxx Chatsko]

    Shares of Tahoe Resources (NYSE:TAHO) fell nearly 26% today after the company announced that the Constitutional Court of Guatemala upheld a previous decision from the Ministry of Energy and Mines (MEM) that suspended the operating license of the Escobal silver mine. The news is especially painful because the decision from the mining authority had been overturned by the country's Supreme Court, but now the Supreme Court has been overruled by the Constitutional Court. 

Best Stocks To Buy Right Now: Career Education Corporation(CECO)

Advisors' Opinion:
  • [By Stephan Byrd]

    Career Education (NASDAQ:CECO) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday.

  • [By Stephan Byrd]

    Career Education Co. (NASDAQ:CECO) – Equities researchers at Piper Jaffray reduced their Q2 2018 earnings per share estimates for shares of Career Education in a note issued to investors on Thursday, May 3rd. Piper Jaffray analyst P. Appert now expects that the company will post earnings per share of $0.19 for the quarter, down from their previous forecast of $0.24. Piper Jaffray also issued estimates for Career Education’s Q3 2018 earnings at $0.23 EPS, Q4 2018 earnings at $0.29 EPS, FY2018 earnings at $0.95 EPS, Q1 2019 earnings at $0.28 EPS, Q2 2019 earnings at $0.25 EPS, Q3 2019 earnings at $0.29 EPS, Q4 2019 earnings at $0.34 EPS, FY2019 earnings at $1.16 EPS and FY2020 earnings at $1.26 EPS.

  • [By Joseph Griffin]

    Municipal Employees Retirement System of Michigan trimmed its holdings in Career Education Corp. (NASDAQ:CECO) by 28.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,640 shares of the company’s stock after selling 7,590 shares during the period. Municipal Employees Retirement System of Michigan’s holdings in Career Education were worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Joseph Griffin]

    Career Education Corp. (NASDAQ:CECO) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $16.60 and last traded at $16.55, with a volume of 19843 shares trading hands. The stock had previously closed at $16.52.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Career Education (CECO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Saturday, February 9, 2019

Zynga (ZNGA) Releases Quarterly Earnings Results

Zynga (NASDAQ:ZNGA) announced its quarterly earnings results on Wednesday. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02), reports. Zynga had a return on equity of 1.13% and a net margin of 1.70%. The business had revenue of $248.69 million during the quarter, compared to the consensus estimate of $245.78 million. During the same quarter last year, the company earned $0.01 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year.

ZNGA stock traded up $0.14 during midday trading on Friday, reaching $4.88. 12,574,800 shares of the company’s stock traded hands, compared to its average volume of 14,742,215. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of 244.00, a PEG ratio of 2.00 and a beta of 0.43. Zynga has a 52 week low of $3.20 and a 52 week high of $4.89.

Get Zynga alerts:

In other Zynga news, COO Matthew S. Bromberg sold 8,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $3.56, for a total transaction of $28,480.00. Following the completion of the sale, the chief operating officer now directly owns 548,794 shares in the company, valued at $1,953,706.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey Miles Ryan sold 127,194 shares of the stock in a transaction dated Friday, January 18th. The stock was sold at an average price of $4.32, for a total transaction of $549,478.08. Following the sale, the insider now owns 1,720 shares of the company’s stock, valued at $7,430.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 442,694 shares of company stock worth $1,777,543. Insiders own 11.87% of the company’s stock.

Several research firms have recently weighed in on ZNGA. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $6.00 price objective on shares of Zynga in a research report on Thursday. Goldman Sachs Group assumed coverage on Zynga in a research report on Wednesday, January 30th. They set a “buy” rating and a $5.30 price target for the company. Stephens initiated coverage on Zynga in a research note on Thursday, January 10th. They issued an “equal weight” rating and a $4.75 price objective on the stock. BidaskClub upgraded Zynga from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 5th. Finally, Barclays set a $4.00 target price on Zynga and gave the stock a “sell” rating in a research note on Sunday, December 30th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.98.

ILLEGAL ACTIVITY WARNING: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.tickerreport.com/banking-finance/4137544/zynga-znga-releases-quarterly-earnings-results.html.

About Zynga

Zynga Inc develops, markets, and operates social games as live services in the United States and internationally. The company's games are played on mobile platforms, such as iOS and Android operating systems, as well as on social networking sites, including Facebook. It also provides advertising services comprising mobile and display ads, engagement ads and offers, and branded virtual goods and sponsorships to advertising agencies and brokers; and software licensing and maintenance services related to NaturalMotion technology, as well as licenses its own brands.

Read More: Futures Contract

Earnings History for Zynga (NASDAQ:ZNGA)

Wednesday, February 6, 2019

Top 10 Blue Chip Stocks To Own For 2019

tags:TRIB,TNAV,TEL,OII,HDS,IPWR,NLST,XON,HSON,DVAX,

April 24, 2018: Markets opened higher again Tuesday but soon sank to losses and just kept falling throughout the trading session. The yield on 10-year Treasury bonds finally topped 3% early this morning and combined with lackluster earnings and cautious guidance from some blue chippers, stocks never had a chance to fly higher. Home prices rose sharply again and sales of new homes also posted a solid gain.

WTI crude oil for June delivery settled at $67.70 a barrel, down 1.4% for the day. June gold added about 0.7% on the day to settle at $1,333.00. Equities were headed for a lower close about 10 minutes before the bell as the Dow traded down 2.03% for the day, the S&P 500 traded down 1.66%, and the Nasdaq Composite traded down 2.04%.

Bitcoin futures (XBTK8) for May delivery traded at $9,410, up about 6% on the CBOE after opening at $8,970 this morning. The digital currency’s trading range for the day was $8,940 to $9,450.

The Dow stock posting the largest daily percentage loss ahead of the close Tuesday was 3M Company (NYSE: MMM) which traded down 6.99% at $200.78. The stock’s 52-week range is $192.36 to $259.77. Volume was about four times the daily average of around 2.7 million shares. The company reported so-so results this morning and lowered earnings guidance.

Top 10 Blue Chip Stocks To Own For 2019: Trinity Biotech plc(TRIB)

Advisors' Opinion:
  • [By Ethan Ryder]

    Trinity Biotech (NASDAQ: TRIB) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

  • [By Max Byerly]

    Trinity Biotech (NASDAQ: TRIB) is one of 25 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Trinity Biotech to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.

Top 10 Blue Chip Stocks To Own For 2019: TeleNav Inc.(TNAV)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Telenav (TNAV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    ValuEngine upgraded shares of Telenav (NASDAQ:TNAV) from a sell rating to a hold rating in a research note published on Saturday.

    Several other equities research analysts also recently issued reports on TNAV. BidaskClub upgraded Telenav from a sell rating to a hold rating in a report on Friday. Zacks Investment Research upgraded Telenav from a sell rating to a hold rating in a report on Thursday, April 5th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $11.17.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Telenav (TNAV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Blue Chip Stocks To Own For 2019: TE Connectivity Ltd.(TEL)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on TE Connectivity (TEL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    United Capital Financial Advisers LLC boosted its position in TE Connectivity Ltd (NYSE:TEL) by 18.5% during the 1st quarter, HoldingsChannel reports. The fund owned 11,098 shares of the electronics maker’s stock after acquiring an additional 1,736 shares during the quarter. United Capital Financial Advisers LLC’s holdings in TE Connectivity were worth $1,109,000 as of its most recent SEC filing.

  • [By Ethan Ryder]

    TE Connectivity Ltd (NYSE:TEL) has been given a consensus recommendation of “Buy” by the fourteen research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $114.30.

  • [By Joseph Griffin]

    Telcoin (CURRENCY:TEL) traded down 5.5% against the dollar during the 24-hour period ending at 14:00 PM ET on September 2nd. Over the last seven days, Telcoin has traded 20.9% higher against the dollar. Telcoin has a market capitalization of $25.25 million and $119,035.00 worth of Telcoin was traded on exchanges in the last day. One Telcoin token can now be purchased for $0.0008 or 0.00000011 BTC on popular exchanges including Kucoin, HitBTC, EtherDelta (ForkDelta) and IDEX.

  • [By Max Byerly]

    Allianz Asset Management GmbH raised its stake in TE Connectivity Ltd (NYSE:TEL) by 16.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,613,642 shares of the electronics maker’s stock after buying an additional 225,677 shares during the period. Allianz Asset Management GmbH owned about 0.46% of TE Connectivity worth $161,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Max Byerly]

    Achmea Investment Management B.V. increased its stake in TE Connectivity Ltd (NYSE:TEL) by 2.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 235,540 shares of the electronics maker’s stock after purchasing an additional 6,726 shares during the quarter. Achmea Investment Management B.V. owned approximately 0.07% of TE Connectivity worth $18,665,000 as of its most recent filing with the Securities and Exchange Commission.

Top 10 Blue Chip Stocks To Own For 2019: Oceaneering International, Inc.(OII)

Advisors' Opinion:
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Oceaneering International (OII)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    I've written previously about my belief that shrinking oil inventories and rising crude oil prices will spark a recovery in energy services stocks, and I've already explained why Core Labs and Hess Corp are favorite stocks of mine to buy. Now, after reviewing Oceaneering International's (NYSE:OII) first-quarter results, I'm increasingly convinced that it's a great time to add this stock to any portfolio.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Oceaneering International (OII)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Benzinga News Desk]

    Shari Redstone is one “disloyal” media heiress, according to CBS (NYSE: CBS): Link

    ECONOMIC DATA US Initial Jobless Claims for May 18 234.0K vs 220.0K Est; Prior 222.0K. US Continuing Claims for May 11 1.74M vs 1.75M Est; Prior 1.71M Existing home sales report for April will be released at 10:00 a.m. ET. The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET. Atlanta Fed President Raphael Bostic will speak at 10:35 a.m. ET. The Treasury is set to auction 7-year notes at 1:00 p.m. ET. The Kansas City Fed manufacturing index for May will be released at 11:00 a.m. ET. Philadelphia Federal Reserve Bank President Patrick Harker is set to speak at 2:00 p.m. ET. Data on money supply for the latest week will be released at 4:30 p.m. ET. ANALYST RATINGS UBS upgrades Deere (NYSE: DE) from Neutral to Buy Wells Fargo upgrades Oceaneering (NYSE: OII) from Market Perform to Outperform Canaccord downgrades Vermillion (NASDAQ: VRML) from Buy to Hold Wedbush downgrades Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Max Byerly]

    First Trust Advisors LP grew its holdings in shares of Oceaneering International (NYSE:OII) by 172.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 812,975 shares of the oil and gas company’s stock after buying an additional 514,553 shares during the period. First Trust Advisors LP’s holdings in Oceaneering International were worth $20,698,000 as of its most recent SEC filing.

  • [By Ethan Ryder]

    Eagle Boston Investment Management Inc. raised its holdings in Oceaneering International (NYSE:OII) by 4.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 231,939 shares of the oil and gas company’s stock after purchasing an additional 9,733 shares during the quarter. Eagle Boston Investment Management Inc.’s holdings in Oceaneering International were worth $5,905,000 as of its most recent filing with the SEC.

Top 10 Blue Chip Stocks To Own For 2019: HD Supply Holdings, Inc.(HDS)

Advisors' Opinion:
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on HD Supply (HDS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Andra AP fonden purchased a new position in shares of HD Supply Holdings Inc (NASDAQ:HDS) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 308,500 shares of the industrial products company’s stock, valued at approximately $13,232,000. HD Supply makes up 0.4% of Andra AP fonden’s investment portfolio, making the stock its 2nd largest position.

  • [By Max Byerly]

    Element Capital Management LLC acquired a new stake in HD Supply Holdings Inc (NASDAQ:HDS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 25,666 shares of the industrial products company’s stock, valued at approximately $974,000.

  • [By Logan Wallace]

    Rhumbline Advisers cut its stake in HD Supply Holdings Inc (NASDAQ:HDS) by 7.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 181,854 shares of the industrial products company’s stock after selling 14,628 shares during the period. Rhumbline Advisers owned about 0.10% of HD Supply worth $7,800,000 as of its most recent SEC filing.

Top 10 Blue Chip Stocks To Own For 2019: Ideal Power Inc.(IPWR)

Advisors' Opinion:
  • [By Max Byerly]

    Headlines about Ideal Power (NASDAQ:IPWR) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ideal Power earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the industrial products company an impact score of 46.8284728476176 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Ideal Power (IPWR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    News articles about Ideal Power (NASDAQ:IPWR) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ideal Power earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave press coverage about the industrial products company an impact score of 47.3748047378114 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Top 10 Blue Chip Stocks To Own For 2019: Netlist, Inc.(NLST)

Advisors' Opinion:
  • [By Money Morning Staff Reports]

    After looking at last week's top performing penny stocks, we'll show you a small-cap stock with real growth potential that just popped up on our radar…

    Penny Stock Current Share Price Last Week's Gain New Age Beverage Corp. (NADAQ: NBEV) $3.94 286.79% India Globalization Capital Inc. (NYSE: IGC) $2.18 181.55% Ascent Capital Group Inc. (NASDAQ: ASCMA) $2.16 103.85% Netlist Inc. (NASDAQ: NLST) $0.73 80.56% Oragenics Inc. (NYSE: OGEN) $0.92 71.63% Astrotech Corp. (NASDAQ: ASTC) $3.44 68.37% Command Security Corp. (NYSE: MOC) $2.77 51.09% Oasmia Pharmaceuticals (NASDAQ: OASM) $3.57 50.66% NovaBay Pharmaceuticals Inc. (NYSE: NBY) $2.10 48.15% Navidea Biopharmaceuticals Inc. (NYSE: NAVB) $0.25 45.72%

    While the gains these stocks made are exciting, they also highlight the danger of investing in penny stocks.

  • [By Stephan Byrd]

    Netlist, Inc. (NASDAQ:NLST)’s share price traded down 6.3% during trading on Tuesday . The stock traded as low as $0.17 and last traded at $0.17. 2,960 shares changed hands during trading, a decline of 100% from the average session volume of 2,102,591 shares. The stock had previously closed at $0.16.

  • [By Money Morning News Team]

    On Sept. 11, Netlist Inc. (NASDAQ: NLST) gained 542% in the wake of news that the company had been victorious in a patent lawsuit.

    This ruling related to one of the company's most lucrative patents. While not conclusive, CEO C.K. Hong says that this latest development will allow a final decision by the U.S. International Trade Commission within the next several months.

  • [By Money Morning News Team]

    On Sept. 11, Netlist Inc. (NASDAQ: NLST) gained 542% in the wake of news that the company had been victorious in a patent lawsuit.

    This ruling related to one of the company's most lucrative patents. While not conclusive, CEO C.K. Hong says that this latest development will allow a final decision by the U.S. International Trade Commission within the next several months.

Top 10 Blue Chip Stocks To Own For 2019: Intrexon Corporation(XON)

Advisors' Opinion:
  • [By Keith Speights]

    Shares of Intrexon Corporation (NYSE:XON) were up 28.5% as of 11:19 a.m. on Monday. The biotech announced what it said were "advances in production of medical cannabis." In particular, Intrexon stated that its scientists had engineered a yeast strain that could be used in a microbial fermentation process to produce cannabinoids at low cost.

  • [By Todd Campbell]

    After the company reported disappointing first-quarter financial results, including worse-than-expected revenue performance, shares in Intrexon Corp. (NYSE:XON) were down by 20% at 3:15 p.m. EDT Friday.

  • [By Peter Graham]

    Small cap synthetic biology Intrexon Corp (NYSE: XON) has elevated short interest of 33.93% according to Highshortinterest.com. Intrexon Corp says its "powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet." The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function and performance of living cells. 

Top 10 Blue Chip Stocks To Own For 2019: Hudson Global, Inc.(HSON)

Advisors' Opinion:
  • [By Shane Hupp]

    JBF Capital Inc. purchased a new position in Hudson Global Inc (NASDAQ:HSON) in the second quarter, Holdings Channel reports. The fund purchased 157,917 shares of the business services provider’s stock, valued at approximately $256,000.

Top 10 Blue Chip Stocks To Own For 2019: Dynavax Technologies Corporation(DVAX)

Advisors' Opinion:
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By William Romov]

    If a biotech stock's clinical trial results are positive, or receives a nod of approval from the FDA, then the stock can soar. For example, last year Dynavax Technologies Corp. (Nasdaq: DVAX) shares more than quadrupled between May 31 and Oct. 5, when it climbed 337.6%, from $5.50 to $24.07.

  • [By Lisa Levin] Gainers ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook. vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results. RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter. Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales. Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings. MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma. New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor. Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session. Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
  • [By Lisa Levin] Gainers Turtle Beach Corporation (NASDAQ: HEAR) surged 87.1 percent to $12.98 after the company reported Q1 results and raised its FY18 outlook. ARMO BioSciences, Inc. (NASDAQ: ARMO) shares jumped 66.8 percent to $49.735 after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. vTv Therapeutics Inc. (NASDAQ: VTVT) gained 34 percent to $2.2920 following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Prestige Brands Holdings, Inc. (NYSE: PBH) climbed 22.3 percent to $34.84 after the company posted upbeat Q4 earnings. Depomed, Inc. (NASDAQ: DEPO) shares jumped 22.2 percent to $7.28 following better-than-expected Q1 earnings. Everspin Technologies, Inc. (NASDAQ: MRAM) gained 19.8 percent to $8.89 after the company reported strong results for its first quarter. Luxfer Holdings PLC (NYSE: LXFR) surged 19.8 percent to $17.10 following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 18.3 percent to $2.26 after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Intelligent Systems Corporation (NYSE: INS) gained 17 percent to $7.116. Green Dot Corporation (NYSE: GDOT) surged 15.3 percent to $73.00 after reporting upbeat Q1 earnings. The Chefs' Warehouse, Inc. (NASDAQ: CHEF) climbed 15 percent to $28.85. Chefs' Warehouse posted Q1 earnings of $0.03 per share on sales of $318.6 million. Westport Fuel Systems Inc. (NASDAQ: WPRT) rose 14.2 percent to $2.9701. Wright Medical Group N.V. (NASDAQ: WMGI) jumped 13.8 percent to $23.87 after reporting upbeat quarterly earnings. Diplomat Pharmacy, Inc. (NYSE: DPLO) gained 13.4 percent to $22.70. Diplomat named Brian Griffin as Chairman and CEO. Carvana Co. (NYSE: CVNA) shares rose 13 percent to $27.97 after reporting upbeat Q1 sales. Prothena Corporation plc (NASDAQ: PRTA) gained 12 percent to $15.19
  • [By George Budwell]

    Over the past few years, however, several beaten-down biotech stocks have ended up producing enormous gains for risk-tolerant investors. For example, Acadia Pharmaceuticals (NASDAQ:ACAD), Exelixis (NASDAQ:EXEL), and Dynavax Technologies Corporation (NASDAQ:DVAX) were all once so-called "penny stocks" that went on to rebound nicely once their lead clinical candidates made it successfully onto the market.

  • [By Cooper Creagan]

    The same is true for Dynavax Technologies Corp. (Nasdaq: DVAX). A quick Night Trade of DVAX would've netted a whopping 230% in just a few months – and this can all be done from the comfort of your own home.

Tuesday, February 5, 2019

Defense Industry Update

A deep dive into the U.S. defense industry, including how recent Washington budget battles are shaping the outlook for contractors, and a tour of some of the Pentagon's big-budget spending priorities.

Motley Fool's host Nick Sciple and Fool.com contributor Lou Whiteman discuss the outlook for the defense industry, including factors that should excite, and worry, investors.

A full transcript follows the video.

This video was recorded on Jan. 31, 2019.

Nick Sciple: Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day. Today is Thursday, January 31, and we're talking about the defense industry. I'm your host, Nick Sciple, and today I'm joined by Motley Fool contributor Lou Whiteman via Skype. How's it going, Lou?

Lou Whiteman: I'm doing well! How are you? 

Sciple: I'm doing great! We've got the polar vortex coming through, single-digit windchills here in the D.C. area. Being from Alabama, it's been a little bit of an adjustment, but we're making it through. How are you doing in your neck of the woods? 

Whiteman: We are 33 degrees. I just looked out the window, we're 33 degrees in Atlanta, which I guess sounds pretty warm compared to up there, but I'm sick of it. I'm ready for spring.

Sciple: Yeah, tell me about it. I'm ready for shorts weather coming back through. 

Today, we're talking about the defense industry. We're going to talk about several different things. We're going to talk about what's been going on with the government shutdown, and we're going to talk about what the government has been talking about when it comes to the needs of the military into the future. But first, Lou, before we dive too deep into that, I want you to talk about, how significant is the government as a customer for these defense contractors? How important is what's going on in Washington, D.C., to their bottom line?

Whiteman: This is the trade-off of this industry. The good news is, you have a customer who, so far, for 200 years in, has been able to pay its bills, and it's pretty reliable on that. However, you are reliant on that one customer, and increasingly in recent years, there has been erratic behavior with that customer. In this case, the Pentagon was not shut down, which certainly helps these defense contractors, but they do a lot more than just serve the Pentagon. They do a lot of the IT work for different agencies that were shut down. They do a lot of work for NASA and Homeland Security, who were involved in the shutdown. So, yeah, this adds a huge layer of uncertainty to a business that is, as you say, very reliant on that one customer.

Sciple: Just to give you some numbers on the shutdown, obviously it was the longest one in history at 35 days, and we're still not 100% sure whether it's over for good. We've got this continuing resolution in place that's going to keep the government temporarily open until February 15, but there could be another shoe to drop. Definitely some uncertainty for these defense contractors.

One way that these defense companies were impacted during the shutdown was the ability to follow through on some foreign arms sales that had been taking place recently because the Department of State and Department of Commerce were both shut down. Can you talk about the effects of that on some of the defense contractors in the U.S.? 

Whiteman: Sure. As you say, for all these foreign sales, there's a few different programs that we do foreign sales. Some through the State Department, and some just need approval from Commerce. But they do need to be rubber-stamped. Sometimes, it can be controversial.

International sales are a big push of this administration, and are expected to grow. It was over $55 billion last year. They're hoping for more this year. This is a significant chunk of revenue that did shut down. The good news is, it was early in the quarter. We're mostly talking about the first quarter of 2019. There's a lot of time to play catch-up. The State Department officials really believe that it won't mess up the year. It could have a small effect in the first quarter of 2019, but hopefully, they're back at work. Most of what was in the pipeline was pretty noncontroversial, so it should be a matter of just getting it out the door. But that's certainly a huge risk, more for the first quarter of 2019, but a huge risk for these companies and their numbers. 

Sciple: Sure. Outside of the foreign arms sales, were there any companies in particular that may have been more affected by the shutdown than others? How did those chips fall across the industry and the companies that operate in it?

Whiteman: Fortunately for the big guys, they're big companies. Again, this is mostly a first quarter 2019, early in the quarter, so there's a lot of time for reimbursement, a lot of time to catch up. One company that it feels like could be impacted more than others is SAIC, which is a government services contractor. They do a lot of IT work. They do a lot of work with systems, they have a lot of work with NASA. They're unfortunately on a calendar that their quarter ends January 31. So, they're both a smaller-revenue company, so any hit is going to be felt disproportionately, and, in the current quarter, it's all going to be soaked up. They've been pretty public warning Wall Street that there could be an impact to the current quarter, which makes me think that it is a concern. There was a number, it's a few weeks old now, but on January 7, they met with investors and said it was a $50 million impact so far, plus maybe about $10 million in employee compensation for work being not done that's going to have to be, hopefully, reimbursed. It's a company with a little over a billion dollars in revenue expected in the quarter. With how long the shutdown went, it definitely could take a toll on their eventual quarter that ends at the end of the month.

Sciple: That will be our first look at how any of these companies was affected by the shutdown. We had a lot of defense contractors reporting earnings in this past week. Lockheed Martin (NYSE:LMT), General Dynamics (NYSE:GD), Raytheon (NYSE:RTN), Northrop (NYSE:NOC). Of course, those numbers are not embracing a significant chunk of the government shutdown. However, they did give relatively muted guidance looking out into next year. Can you talk about that a little bit? 

Whiteman: Sure. Yeah, this is earnings weeks for these companies, so we're just digesting them now. All of the big four -- Lockheed, Northrop, General Dynamics, and Raytheon -- have surprised me, and I think surprised the markets, with their conservative guidance. A lot of what you're seeing is uncertainty about when some of these big, long, multiyear items are going to actually get paid, and how quickly things will happen. 

Lockheed Martin took the step of adding impact of government shutdown to their forward-looking statements as a possible thing that could go wrong. As far as I know, that's brand-new. That wasn't there before. They're the biggest defense contractor in the world, and even at their scale, this is something that they're thinking of, something that they're factoring into what could go wrong for them, especially given the budget negotiations that are coming up on the horizon.

Sciple: Let's talk about that a little bit. With this shutdown lasting for as long as it has, it really highlights the divisions between the two parties in Congress and this inability to come to an agreement. When you look at the 2020 budget, those two groups reaching an agreement as to how much money we're going to spend on defense and the rest of the government is really important to the thesis for these defense contractors. Can you talk about the uncertainty of what we're looking at into the 2020 budget, and how we should think about that as investors?

Whiteman: Yeah, very much so, this is something investors have to be watching. To give you a quick history, right now, we're still working under the Budget Control Act of 2011. If you remember back to the previous administration, we had a split government, and they weren't doing a great job of coming to an agreement on things like budgets. Lawmakers passed a law basically saying, "If you can't compromise, then on both the defense and the civil side, there's going to be sequestration," which was a massive, across-the-board cut. That actually went into effect. It was not enough of a threat to force them to compromise. Defense stocks were hit pretty hard during that time.

With the new administration, we had a couple of years of unified government. We had a two-year budget deal that included Pentagon funding. That's why they weren't part of the shutdown. A lot of people don't realize, that was only a two-year deal. We're coming up now on fiscal 2020. Without a new compromise, we're going to revert back to those sequestration levels. I've seen estimates all across the board, and there's a lot of accounting tricks you can do, but this could cost the Pentagon upwards of $100 billion in spending per year. They can't stop paying the troops, so a lot of that is going to be deferred procurement or deferred modernization of IT.

This recent shutdown was the appetizer to the main course, which is that 2020 budget. Seeing how that played out, it's really hard to have a lot of optimism right now that the budgeting process will go smoothly. Hopefully, they can eventually get something done. I'm not predicting we're going to return to sequestration, but it's a huge risk. It's something you have to be watching. Long-term, I think the companies will be fine. Long-term, as we'll talk about later, there are a lot of things that need to be done, a lot of spending that needs to be done. But this could certainly impact 2019 spending. It could certainly even go into 2020 if the deal is reached late, if there's uncertainty, or if they kick the can and projects have to be delayed.

Sciple: If we go into sequestration, what kind of adjustments might these big contractors have to make to their operations to absorb that and wait out the low times until we can reach another consensus in Congress?

Whiteman: How they modeled it last time -- and unfortunately, they have recent history here -- a lot of the big needle-moving projects for these companies, they're not going to disappear. We're not going to stop buying aircraft carriers, we're not going to stop buying F-35s. They can sort of proceed as business as usual, although they might have to slow the scale or slow productivity. For near-term results, for quarterly results, it creates ugly comparisons, and it definitely slows the business down. You have to be a long-term investor to weather that storm. What we learned last time, and I think we'll learn this time, is that in the end, there will be a resolution. But really, what we saw is these companies that just did what they could on the expense side and slowed production to levels that they thought the government was going to order. 

The real companies that got hit are, we like to call them the Beltway bandits, the government IT companies that are increasingly important. A lot of the IT is being outsourced by the government. Those projects are the ones that were really easy to bring to a halt. I would anticipate those companies -- SAIC being one, Leidos (NYSE:LDOS) is a huge one -- those are the companies that are going to be the hardest-hit if we do indeed hit sequestration again. 

Sciple: Something to watch for investors. Lou, you mentioned the long term. Let's talk about the long term and where the bull case might be on a lot of these defense contractors. There's going to have to be a lot of spending when it comes to our arsenal in the future. There are two things we want to talk about -- investment in the nuclear triad, really bringing that up to modernity, as well as, later in the show, we'll talk about the new Missile Defense Review that came back in January. 

When it comes to our nuclear arsenal, it's really reaching the end of its useful life. We're going to have to put some serious investment in to bring those resources up to date. What can you say about what needs to be done when it comes to our nuclear arsenal? How much money is going to need to be pumped into those resources?

Whiteman: The big overriding themes -- and this applies here, and it applies, as we'll talk about later, to things we all know. The world is not getting safer. It's a dangerous place, and we do need weaponry. The second part is, we're now paying the price for the so-called Cold War dividend. When the Cold War ended, the United States was the only superpower. Not that the Pentagon spending went away, but we did go into a lull. And we're now using Cold War-era technology, competing with, in theory, a resurgent Russia, a resurgent China. And, yes, that means spending, that means modernization. 

The CBO [Congressional Budget Office] just updated a study on the triad. They determined almost $500 billion, $494 billion, needs to be spent in the next 10 years on nuclear triad modernization. That's up considerably, 20% or more, from their 2017 estimate. Part of that is, we have a road map for some of this spending. Part of it is, now, we're getting into the years where, hopefully, those investments will be made. So some of that increase was expected. But it's a massive amount, half a trillion is going to go into new bombers, new subs, new rockets, new warheads to put on them, plus all the support. It's a huge area. The details, some of them have to be worked out, but it's almost guaranteed revenue for some of these companies, the lucky winners of these, because it's a huge priority for the United States. 

Sciple: Lou, you alluded to this, and I should have asked you this off the top -- for our listeners who may not be familiar, can you talk about what the nuclear triad is? What does it mean when we say the nuclear triad? 

Whiteman: Sure. There's three ways that we deliver nuclear weapons. We have our missiles, we have bombers, and then we have our submarines, which is perhaps the most important, because that's the deterrent. It's a grim Cold War tale, but the idea was, we needed to be able to launch, and we also needed to be ready for the event that we were surprised. And even if the homeland was decimated, if there's a submarine out there that can quickly respond, that's the best deterrent against launching into the United States. 

It's the formula that's still in place. There's some debate about some parts of it, but this is how we defend the country. This is how we think of nuclear weapons. And all of our equipment is getting old. It's time for renewal. These are big-ticket items, unfortunately for the United States' spending. 

Sciple: Let's talk about some of these items. Northrop Grumman is developing a new bomber, the B-21. The number that I saw is, between now and 2028, the Pentagon is expected to spend $49 billion on that program. Can you talk about the significance of that aircraft for Northrop Grumman, as well as for our defense arsenal as a country? 

Whiteman: That's the keystone project for Northrop Grumman. They won that bomber. It's been a slow road. Of all the parts of the triad, that's probably the most controversial simply because, even though it's stealth, with technology, it's increasingly hard to get a bomber in place over an enemy in a war zone. 

This is a huge expense. They're doing their best to modernize it. It's replacing an aircraft that isn't that old, the stealth bomber from our youth, in part because there's a feeling they did not forward-proof that enough. The downside is, they are trying to forward-proof this one, but it's incredibly expensive. This is a plane that's going to be a significant portion of Northrop Grumman's revenue for the years to come. There's a set number in place. The Air Force, if anything, says we need more of those. The Air Force is trying to expand its fleet in both attackers and bombers. There's no way this is going to be cut completely. 

There is a little bit of long-term risk to Northrop, though, if this project will ever be what they hope it will be, which is over $50 billion, a monster that's a huge portion of the revenue well into the next decade.

Sciple: Let's talk about another monster program, and that's the new submarines that are being developed currently, the Columbia-class sub under development. The numbers I saw there is that there are 12 subs planned at a cost of $107 billion over the next 10 years. Again, same as for the bomber, can you talk about the importance of that program both for the defense contractors who are developing it as well as for our defense capabilities?

Whiteman: Naval is a big part of the bull story on General Dynamics. They're not as exposed to some of this aerospace, and they're not as big on space as some of the other contractors. They have a lot of Army land gear, which, while modernizing, isn't as sexy and doesn't tend to be as big-ticket as the submarines or aircraft. 

This is out of General Dynamics' Electric Boat subsidiary. They're working with Huntington Ingalls. That's our nuclear carrier contractor. They'll get some revenue here, too. This is a boat that, as I said, is designed to be the deterrent. This the reason why a foreign power does not want to attack the United States. Even if they work, even if they get the sneak on us, there are these state-of-the-art submarines out there with brand-new warheads that can fire back. There is, again, some debate over how many we need. A lot of the numbers, the dozen or so, is based on Cold War planning. These are better submarines. However, you do want them patrolling the whole ocean. I would be shocked if we don't get a full allotment of this. 

General Dynamics has had a lot of things going not their way in recent years. Columbia-class is early. It's not really a contributor to earnings right now. But, again, if you look out a few years, one of the reasons why General Dynamics works as an investment is that the Columbia-class, as it matures, is going to see margins. It's a priority, we're not going to see it cut back, and there's pretty reliable revenue streams out of that going out a long time. In the investing world, you don't get that with many sectors. 

Sciple: You said full set. When we're talking about that, how big or small is that relative to the dozen that we're talking about?

Whiteman: Oh, I meant the dozen. Some of the Navy would like to see more. I'd be surprised with that. There's an outside chance you might see that shaved, but that would be in the out year of this decade we're talking about. If there's risk to that program, you have to go out nearly a decade to find it. I think that's a pretty reliable program for General Dynamics, as far as we can reasonably look out.

Sciple: Sure. To close out the triangle of the nuclear triad, let's talk about what is being developed when it comes to our missile capabilities. Currently, Boeing's (NYSE:BA) Minuteman is the only operational ICBM [intercontinental ballistic missile] in the arsenal. There's a priority to come up with a new delivery vehicle, or at least new options for how we can deliver our warheads. Can you talk about what's going on when it comes to that program, and what companies are involved?

Whiteman: Sure. The Minuteman, it's been modernized, but this is, again, a 1960s rocket that we're using. Due to treaties and due to cost cuts, we used to have a number of ICBMs; now we don't. The Minuteman is our go-to rocket. It needs to be replaced. That's the only part of this triad that we don't know who the eventual winner is. It's going to be a big deal for either Northrop or Boeing. Right now, Northrop and Boeing each have about $300 million to develop their model. It's going to be an old-fashioned bake-off for a very large deal. Northrop spent $10 billion to buy Orbital Sciences in part for this in particular. There's a lot that they'd like to do in space, and space is definitely an area that they think they're going to see growth in. 

But the Minuteman, the ability to offer the whole package, for Northrop, which doesn't have Boeing's commercial exposure and which does have some programs -- it does have the B-21 -- this would be a very big win for Northrop. This almost would justify the Orbital Sciences deal or not. They want it. Boeing definitely wants it, too. It's going to be very interesting. It's not going to come this year, but it's going to be very interesting to watch this. You don't get this big of a contract coming up very often, and we don't have a lot of them on the horizon right now.

Sciple: Across this nuclear triad, the takeaway for investors is, there's a lot of money on the table up for grabs. It's something that's key to our defense arsenal coming into the future, so we're going to have to spend the money on it sooner or later. Definitely going to be a bullish sign for these defense contractors going forward. 

Whiteman: Exactly right. You can maybe wonder about individual quarters and exact timing, but over the long haul, if you're a long-term investor, this is pretty close to guaranteed, that these programs are going to be invested in, and this is revenue that's going to be coming in.

Sciple: OK, Lou, let's talk about the Missile Defense Review that I mentioned earlier. It came out on January 17. It's focused on improving the United States' ability to defend against missile attacks. Sometimes they say defense is the best offense. Maybe that's what we're thinking about from our military perspective today. Can you talk about what was on that wish list, when it comes to the new Missile Defense Review, and break that down for us a little bit? 

Whiteman: Sure. This is part of a change in focus at the Pentagon. We spent a lot of time focused on fighting insurgents mostly in the Middle East. There's a renewed focus on major-power conflict, as they call it, which sounds lovely, I know. Part of this is looking at where Russia and China are today, and how we stack up. One area, hypersonics, missiles that travel five times the speed of sound. Arguably, Russia is ahead of us. Arguably, China might even be ahead of us. These are missiles that our current defenses can't even begin to deal with. We need to change that. We also need our own offerings. We are behind in having our own offering to counter that. 

This an area where we are already seeing Pentagon spending. This an area where Lockheed Martin really stands out. They won $1.4 billion in contracts last year, one of them, the Pentagon in their notes justifying that contract said, "No other contractor has this level of design maturity," and talked about hundreds of millions of dollars in redundant costs if they went with anyone other than Lockheed Martin, just to get that other contractor up to speed. 

This isn't going to be a $50 billion area like the bomber, but this is an area where you're going to see a lot of R&D. The contractors love the R&D because it ends up in other places, the famous Lockheed Skunk Works, things like that. This is an area that's really going to fuel the R&D inside of Lockheed and inside some of these contractors for years to come.

Another area is Missile Defense. The THAAD system is another Lockheed system. The Aegis Combat System is the computers that run it, that's another Lockheed system. Raytheon, with its Radar and with its Patriot. Raytheon has the radars that run to THAAD. It has its Patriot missiles. These are all good systems. THAAD has been in the news a lot because it's our primary deterrent to North Korea. But none of them are ready for a hypersonic world. We have got to figure that out. The most likely cost-efficient way is to pay these contractors to make the existing systems better. That is, again, a huge opportunity for Lockheed, and a huge opportunity for Raytheon.

Sciple: Yeah, the significance of these hypersonic weapons, and that they're too fast for our defense capabilities to stop them, it's really something that's important for us to defend against and to have in our offering. 

Another thing on the wish list when it comes to our Missile Defense repertoire takes place in space. We're seeing initiatives to install more sensors in space to be able to track missiles and weapons as they travel in that arena. Can you talk a little bit about what the Pentagon is asking for when it comes to space, and what we're doing there?

Whiteman: Sure. I should say, this is perhaps the most interesting part of the conversation; however, it's probably the least certain. I said before that the submarines are going to get bought, the bombers are going to get bought. A lot of the Missile Defense space right now, it's, in some cases, discussing technologies that haven't yet been invented, or at least improved to the point where they could actually be put in place. There are things that are going to get spent. You mentioned sensors. We need to be able to know the second a launch happens that it happened anywhere in the world. That's increasingly difficult in the world of modern rockets. The Congress has authorized Pentagon to spend the money to figure out how to solve this problem. It could be new military-grade satellites. It could be attachments to commercial satellites. I think the most likely option is a massive fleet of small satellites that can blanket the whole world. 

A lot of this classified. We don't know where it is. We don't know how close it is. We may not even really get a clear picture of what they eventually choose to do. One company I'd look at, though, it's a very under-the-radar defense company, Harris Corporation, which does defense electronics and sensors. Their CEO on the conference call mentioned the potential for a massive new constellation of classified small satellites on the horizon as a real chance for the company to grow. I'm pretty sure he was talking about this space sensor layer. It could be an indication of where he hopes the Pentagon goes, it could be an indication of where he's been led to think the Pentagon is going to go. Harris, Boeing, Raytheon, Northrop -- all these companies will definitely benefit from that.

Sciple: It appears that space is becoming a more and more significant part of our defense initiatives. You had the Space Force announcement a few months ago from the president. Part of this Missile Defense Initiative has to do with being able to actually shoot down missiles in space. Folks who have been around for a while might remember the Reagan "Star Wars" program back in the '80s, and the shopping list has not changed in 30 years. Can you talk a little bit about what we're looking to attempt to do, probably over the long term, when it comes to satellites intercepting missiles in space?

Whiteman: You're right, this is Star Wars all over again. The concept is the same. We've progressed a lot technologically since the Reagan years. It's technically feasible, but that doesn't mean it's likely. It's still very hard. What we're talking about here is the ability to shoot an ICBM down. You have to do that right at the launch phase to really be successful. Now, to do that, you only have a window of maybe seconds. To be able to have something in space capable of detecting and launching within seconds, we need to have these satellites everywhere, including lots of satellites over enemy territory. 

The logistics, if you're talking about a rocket shooting through the atmosphere and getting to the launch phase to detect and do it, maybe thousands of these armed satellites in space to make this possible. Again, technically, can we do it? Can we shoot down a rocket? Yes. That's what the Patriot's been doing. That's what the THAAD's been doing. There's a new Raytheon system that does it. All of these, from the ground. But having them in place so it's an effective weapon or effective defense, that's a really, really complicated and really, really expensive proposition, especially since right now, we're only targeting these at about 50%, so you need some redundancy built in there, which just means all the more rockets.

Sciple: It sounds like a very difficult engineering problem to even make that happen. We talk about the difficulty of hitting a rocket with another rocket, the math to make that work is difficult. Another development we're seeing, though, is that over the longer term, maybe we don't have to have a rocket, we may be able to use a directed-energy [weapon] or a laser or something like that to intercept it. You get the advantage of, it travels at the speed of light. For these hypersonic, extremely fast weapons, it doesn't matter because you're never going to go faster than the light that we're shooting at that. 

Can you talk about the challenges behind that program, both in space, of course, but also a ground-based missile intercept program that operates through a laser delivery?

Whiteman: You're absolutely right. In theory, laser is the solution to a lot of our problems. It's easier to rearm in space, it's much faster. Again, when you're talking about a matter of seconds to get something fired, a laser makes a lot of sense. Unfortunately, easier said than done. If you have the laser in space, it needs a certain amount of energy just to penetrate our atmosphere. If you think about the energy that's already required just to do damage and halt an ICBM, you're talking about an incredibly powerful laser up in space. Are we capable of it? Yes. But the battery requirements, the recharging requirements, it's going to be a huge satellite that, in theory, could be pretty easily targeted itself. The laser helps with timing, but it doesn't mean we just stick one over the United States and that's fine. You may not need thousands, but you need hundreds of very, very expensive, very complex, and somewhat vulnerable satellites out there to make it work. 

It's not reasonable that we're going to see this now. Again, technically, is it possible? Yes. Could we demonstrate it? Yes. But are we going to build a fleet of these that could effectively protect our country anytime soon? That's hard to imagine. At best, from the contractor's perspective, this is intriguing enough that there's going to be R&D. The Defense Department is spreading money around quite a bit in relatively modest amounts just to work on advancing this. But it's an incredibly difficult problem to solve with the battery capacity, the recharging, and just dealing with things in space. We're not ready to solve it. It's still in the drawing board. 

Sciple: Definitely something to watch as we look out over the long term. We talked last week about batteries. This is another instance where battery technology is going to be really important, even touching the defense space.

Whiteman: The bigger-picture thing, too, that we have to consider as we're doing this, is there is a moral dilemma of what we're talking about here -- pretty automated systems in space with lethal weapons. By default, we have to let them work on their own. There is not time for a human to analyze the data, say, "Yes, this indeed a launch. Fire." We have got to get these systems to a point where they can reliably say, "Yes, this an ICBM with dangerous intentions, and it needs to be taken out." There's a real risk that if something goes wrong, there's a laser or a rocket up in space that's going to be launching an attack on a foreign nation when they're just putting up a weather satellite. Hopefully that wouldn't happen. That's an extreme example. But there's a lot to grapple with as we do this. 

Like I said, this is very neat. It's going to be R&D. It's going to be talked about for years to come. I would not invest on this now, though, thinking that this is going to happen within a reasonable time period. 

Sciple: Yeah. Everybody knows about the hype cycle. When it comes to these directed-energy and laser technologies, it's very exciting, the promise, what we can see in the future; but the capabilities to actually carry that out at scale, we're going to need to see some additional R&D before those can really move up.

One last thing I want to mention when it comes to the Missile Defense program, you mentioned this in one of the articles that I read on Fool.com recently, is there new opportunities for these aerospace companies when it comes to Missile Defense; however, some shipbuilders may be impacted as we shift how we structure our Missile Defense resources. Can you talk a little bit about what trickle-down impact that may have outside of the missile industry?

Whiteman: All of our branches of government, as is normally the case, make a case for why they need investment, why they need to expand. I think the Navy's case was the best. The Navy is worn down. The president ran on the idea of a 355-ship fleet -- which would be pretty substantial, we're under 300 right now -- in part because the Navy's role is so vast and its territory is so vast. One of the Navy's important jobs right now is, their destroyers are out on most of the Pacific, but all over the world. They're our eyes and ears for Missile Defense right now. The Aegis System that's on our destroyers is our primary detection system for a lethal threat. Hopefully with these new sensors, and hopefully with this new push to get better at missile detection, the destroyers won't be needed. We're talking years down the line, but the number of missions that these destroyers will have to do for missile deterrence will decrease.

In theory, that should ease the burden on the Navy and perhaps let them get by with fewer ships. Everything we're talking about is so expensive, and we're in a time of budget battles. It's going to be natural to look for ways to reduce overall spending in the next five, 10 years. I think a decent case could be made by lawmakers that, look, as we improve other forms of Missile Defense, we can take this burden off the Navy, maybe we don't need that 355-ship fleet, maybe we don't need to support all of the sailors and all of the support staff that goes with that, which is a huge budget-buster. 

The Navy is still growing. The Navy is going to modernize. General Dynamics and Huntington Ingalls are the two contractors most tied to the Navy. This isn't a reason to sell them, but it's certainly something that investors should watch. I think a reasonable case can be made that maybe, the Navy will be able to get by with less with all these other developments going on.

Sciple: Sure. Something to watch for investors, particularly those invested in General Dynamics and Huntington Ingalls. 

Before we go away, we've given a good overview of what's impacting these defense contractors on the short term when it comes to the budget, as well as the opportunities over the long term with these new weapon-delivery vehicles. As you look out into the defense industry today, which company or companies are you most excited about their future prospects?

Whiteman: Lockheed Martin can't help but impress. Lockheed Martin, for years, was tied to the F-35. The F-35 is an amazing program. It's going to be a trillion-dollar program for Lockheed and its subcontractors over the life of the program. What Lockheed has done very well, especially in the last few years, is there's a lot more than just the F-35 to get excited about. We talked about hypersonics, we talked about their Missile Defense and their missiles. There are a lot of ways for Lockheed to win, even looking at the recent earnings. I just wrote something about this. 2019, we'll see what the budget does. But over time, there are so many ways that Lockheed Martin can win. It's a great company to just hold on to and weather the storm. 

Among the big guys, if there was one that feels like a bargain, but I've been saying this a while and they haven't come through for me yet, General Dynamics has been in the penalty box almost since the Great Recession because of its Gulf Stream arm. The business jet industry just has not come back from the recession. I believe Gulf Stream is coming back. I believe as it does, General Dynamics will leave the penalty box, and its multiple relative to its peers will improve. It should outperform its peers. I said that six months ago. We're still waiting. I still believe it. I still like General Dynamics. But I'm losing confidence that this is even a 2019 story, so I would understand investors not jumping in right now.

Sciple: All right, listeners that's two for your watch list in the defense space. Thanks for coming on, Lou, and thanks for talking to us about everything that's going on in this really fascinating industry! I'm happy to have you on soon to follow up!

Whiteman: Sure! 

Sciple: As always, people on the program may own companies discussed on the show, and The Motley Fool may have formal recommendations for or against the stocks discussed, so don't buy or sell anything based solely on what you hear. Thanks to Austin Morgan for his work behind the glass! For Lou Whiteman, I'm Nick Sciple. Thanks for listening and Fool on!

[ending theme]

Sciple: OK, Lou, with Super Bowl Sunday coming up, I'd really be remiss if we didn't talk a little bit about what's going on this weekend. You're in Atlanta. The Super Bowl between the Patriots and the Rams is taking place there this week. What have you seen around town with the prep for the big game upcoming?

Whiteman: It's been fun. There's a lot going on, the Super Bowl Fan Fest experience. I haven't personally gone, but a lot of my friends, a lot of my daughter's friends, have been down there. They put on a good show. There's a lot of concerts this weekend. I'm looking forward to the Foo Fighters Saturday night. We may park outside and watch that. I think there's a football game at some point, but the football game is very much a tiny part of this weekend, which is fun to see. [laughs] 

Sciple: As we talk about the game, do you have anybody you're rooting for on Sunday? Do you have a pick for us? What are you thinking?

Whiteman: For full disclosure, I'm a Saints fan, so I'm probably a little bitter. I refuse to believe a coach 10 years younger than Tom Brady is going to be able to do what nobody else seemingly can do. So, reluctantly -- I know this is not a popular pick -- I just can't pick against the Patriots. 

Sciple: Let's let Austin Morgan in on this talk, go around the horn. What are you thinking for the game on Sunday, Austin?

Austin Morgan: I think if the Rams play a clean game, they might be able to take down the Goliath.

Sciple: I tell you, for me, my heart wants the Rams. I want the young coach, the upstarts, in a new town, a really fun offense, fun team to watch, to come away with it. But my head really says the Patriots. Our listeners who have been listening for a while know I'm an Alabama football fan, so I'll give you a stat. Going back to 2014, every year that New England has won the Super Bowl, Alabama has lost the National Championship. And every year that Alabama has won the National Championship, the Patriots have not won the Super Bowl. And this year, the Alabama Crimson Tide lost to Clemson in the National Championship game.

Whiteman: It's very brave of you to admit that, Nick! [laughs] 

Sciple: Hey, I'm there. And this year, even though my heart doesn't want to say it, I think the Patriots are going to come away with it in Atlanta, just like the Tide did last year at the National Championship game. I don't know how you beat Belichick and Brady. I'm going to be looking forward to watching. Hoping with my hope that the Rams can somehow pull it out. 

Whiteman: Can I end this on a bitter note and say the one thing I'm absolutely sure of is that if Tom Brady needs a touchdown late in the game, that pass interference call will be called if it's the Patriots, not the Saints, that are going up against the Rams' defense.

Sciple: Put your tinfoil hats on, listeners! [laughs] 

Morgan: Maybe they'll give him a little pat on the shoulder, and they'll throw a flag for roughing the passer. 

Whiteman: [laughs] Exactly!

Sciple: All right, folks! We'll all be looking forward to it! We'll come back next week, maybe follow up on what happened in the big game. 

Thanks for coming on, Lou! Let's do it again sometime!